BioStem Technologies: CEO Jason Matuszewski exercised 250,000 shares

What happened

• Jason Matuszewski, CEO, reported exercise or conversion of derivatives on Oct 7, 2026: acquisition of 250,000 shares at $2.00 per share (total $500,000) and a separate derivative disposition of 250,000 shares at $0.00.

Key details

• Transaction date and prices: Oct 7, 2026 — acquired 250,000 shares at $2.00 ($500,000); disposition/conversion of 250,000 derivative shares at $0.00.
• Shares owned after the transaction: not specified in the filing details provided here.
• Relevant footnotes: F1 corrects an earlier over-reporting of one share in prior filings; F2–F4 describe Series A-1 convertible preferred shares (convertible one-to-one, no expiration) and note those shares were omitted from the Form 3 due to an administrative error.
• Filing date and timeliness: filed Oct 9, 2026; the filing is not marked as late.

Why it may matter

• These were derivative transactions: one transaction was an exercise/conversion that required cash payment ($2.00 per share, $500,000); the other reported derivative disposition at $0.00 and is not a market sale.
• A filing does not show why the insider traded or why the company acted.